(Q34495609)

English

Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Yu-Hong Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Yuan Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ling Xue

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jin-Hui Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Min-Hu Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jie Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

29 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

BMC Endocrine Disorders

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

https://scigraph.springernature.com/pub.10.1186/1472-6823-12-30

0 references

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Preoperative detection of gastrointestinal neuroendocrine tumors using endoscopic ultrasonography.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Future aspects of somatostatin-receptor-mediated therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Updated population-based review of carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

A 5-decade analysis of 13,715 carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Gastrointestinal carcinoids: characterization by site of origin and hormone production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Endoscopic ultrasonography of neuroendocrine tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

6 July 2018

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Gastrointestinal carcinoid tumors: factors that predict outcome

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-12-30

21 January 2018

Prognosis and survival in patients with gastrointestinal tract carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526557

27 October 2018

Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23194346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1472-6823-12-30

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34495609&oldid=1552563420"